Evidence map›Paper›PMID 37002787›Full record

ArticleAdvanced healthcare materials2023

Thermophobic Trehalose Glycopolymers as Smart C-Type Lectin Receptor Vaccine Adjuvants.

Aaron T Hendricksen, Shahrzad Ezzatpour, Anunay J Pulukuri, Austin T Ryan, Tatum J Flanagan, William Frantz, David W Buchholz, Victoria Ortega, Isaac A Monreal, Julie M Sahler and 3 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced healthcare materials, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 6 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Aaron T HendricksenDepartment of Chemistry, Washington State University, 1470 NE College Ave, Pullman, WA, 99164, USA.
Shahrzad EzzatpourDepartment of Microbiology and Immunology, Cornell University, 618 Tower Road, Ithaca, NY, 14850, USA.
Anunay J PulukuriDepartment of Chemistry, Washington State University, 1470 NE College Ave, Pullman, WA, 99164, USA.
Austin T RyanDepartment of Chemistry, Washington State University, 1470 NE College Ave, Pullman, WA, 99164, USA.
Tatum J FlanaganDepartment of Chemistry, Washington State University, 1470 NE College Ave, Pullman, WA, 99164, USA.
William FrantzDepartment of Chemistry, Washington State University, 1470 NE College Ave, Pullman, WA, 99164, USA.
David W BuchholzDepartment of Microbiology and Immunology, Cornell University, 618 Tower Road, Ithaca, NY, 14850, USA.
Victoria OrtegaDepartment of Microbiology and Immunology, Cornell University, 618 Tower Road, Ithaca, NY, 14850, USA.
Isaac A MonrealDepartment of Microbiology and Immunology, Cornell University, 618 Tower Road, Ithaca, NY, 14850, USA.
Julie M SahlerDepartment of Microbiology and Immunology, Cornell University, 618 Tower Road, Ithaca, NY, 14850, USA.
Amy E NielsenAstante Therapeutics Inc., 120 N Pine Street, Suite 270A, Spokane, WA, 99202, USA.ORCID 0000-0002-7393-4846
Hector C AguilarDepartment of Microbiology and Immunology, Cornell University, 618 Tower Road, Ithaca, NY, 14850, USA.ORCID 0000-0001-6879-8360
Rock J ManciniDepartment of Chemistry, Washington State University, 1470 NE College Ave, Pullman, WA, 99164, USA.ORCID 0000-0002-3557-8123
Cornell University · USWashington State University · USQ Therapeutics (United States) · US

Funding

Exploiting Cancer Metabolism and Drug Efflux with Bystander-Assisted ImmunotherapyR01CA234115 · NCI · WASHINGTON STATE UNIVERSITY · PI MANCINI, ROCK · 2019 to 2024
$1.6M
AQUISITION OF A 600 MHZ NMR SPECTROMETERS10RR012948 · NCRR · WASHINGTON STATE UNIVERSITY · PI EVANS, JEREMY N · 1998 to 1998
–
NCI NIH HHS R01 CA234115NCRR NIH HHS S10 RR012948
6 · The paper itself

Abstract

Herein, this work reports the first synthetic vaccine adjuvants that attenuate potency in response to small, 1-2 °C changes in temperature about their lower critical solution temperature (LCST). Adjuvant additives significantly increase vaccine efficacy. However, adjuvants also cause inflammatory side effects, such as pyrexia, which currently limits their use. To address this, a thermophobic vaccine adjuvant engineered to attenuate potency at temperatures correlating to pyrexia is created. Thermophobic adjuvants are synthesized by combining a rationally designed trehalose glycolipid vaccine adjuvant with thermoresponsive poly-N-isoporpylacrylamide (NIPAM) via reversible addition fragmentation chain transfer (RAFT) polymerization. The resulting thermophobic adjuvants exhibit LCSTs near 37 °C, and self-assembled into nanoparticles with temperature-dependent sizes (90-270 nm). Thermophobic adjuvants activate HEK-mMINCLE and other innate immune cell lines as well as primary mouse bone marrow derived dendritic cells (BMDCs) and bone marrow derived macrophages (BMDMs). Inflammatory cytokine production is attenuated under conditions mimicking pyrexia (above the LCST) relative to homeostasis (37 °C) or below the LCST. This thermophobic behavior correlated with decreased adjuvant R

Indexed as

Adjuvants, VaccineVaccinesAdjuvants, ImmunologicAnimalsAntibodies, ViralGlycolipidsLectins, C-TypeMiceTrehaloseAdjuvants, ImmunologicAdjuvants, VaccineAntibodies, ViralGlycolipidsLectins, C-TypeTrehaloseVaccinesadjuvantscord factorsC-type lectin receptorsglycopolymersMINCLEthermoresponsive polymers

Identifiers

PMID37002787
PMCPMC11212414
OpenAlexW4362452408

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.